Olanzapine; samidorphan l-malate - Generic Drug Details

What are the generic sources for olanzapine; samidorphan l-malate and what is the scope of patent protection?

Olanzapine; samidorphan l-malate is the generic ingredient in one branded drug marketed by Alkermes Inc and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Olanzapine; samidorphan l-malate has sixty patent family members in twenty countries.

One supplier is listed for this compound.

Summary for olanzapine; samidorphan l-malate

International Patents:	60
US Patents:	14
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for olanzapine; samidorphan l-malate
DailyMed Link:	olanzapine; samidorphan l-malate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for olanzapine; samidorphan l-malate

Constraining patent/regulatory exclusivity:

10,300,054

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for olanzapine; samidorphan l-malate

Drug Class	Atypical Antipsychotic Opioid Antagonist
Mechanism of Action	Opioid Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for olanzapine; samidorphan l-malate

N05AH	Diazepines, oxazepines, thiazepines and oxepines
N05A	ANTIPSYCHOTICS
N05	PSYCHOLEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for OLANZAPINE; SAMIDORPHAN L-MALATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LYBALVI	Tablets	olanzapine; samidorphan l-malate	5 mg/10 mg 10 mg/10 mg 15 mg/10 mg 20 mg/10 mg	213378	3	2025-05-28

US Patents and Regulatory Information for olanzapine; samidorphan l-malate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No	11,241,425
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-001	May 28, 2021		RX	Yes	Yes	9,119,848			Y
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021		RX	Yes	No	11,793,805
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-001	May 28, 2021		RX	Yes	Yes	11,951,111

Expired US Patents for olanzapine; samidorphan l-malate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-004	May 28, 2021	8,252,929
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-001	May 28, 2021	7,262,298
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-002	May 28, 2021	8,252,929
Alkermes Inc	LYBALVI	olanzapine; samidorphan l-malate	TABLET;ORAL	213378-003	May 28, 2021	7,956,187

International Patents for olanzapine; samidorphan l-malate

Country	Patent Number	Title	Estimated Expiration
Spain	2705726
Portugal	2506712
European Patent Office	3446565	PROCÉDÉS POUR LE TRAITEMENT DE LA PRISE DE POIDS INDUITE PAR DES ANTIPSYCHOTIQUES (METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN)
Serbia	65091	POSTUPCI ZA LEČENJE POVEĆANJA TELESNE TEŽINE INDUKOVANOG ANTIPSIHOTICIMA (METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAIN)

Supplementary Protection Certificates for olanzapine; samidorphan l-malate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454436	97C0012	Belgium		PRODUCT NAME: OLANZAPINE; REGISTRATION NO/DATE: EU/1/96/022/001 19960927

Market Dynamics and Financial Trajectory for Olanzapine; Samidorphan L-malate

Last updated: February 15, 2026

---

What is Olanzapine; Samidorphan L-malate and its therapeutic context?

Olanzapine; Samidorphan L-malate is an oral combination product developed to treat psychiatric disorders, primarily schizophrenia and bipolar disorder. Olanzapine is an atypical antipsychotic that manages psychotic symptoms, while samidorphan acts as an opioid receptor antagonist, designed to mitigate olanzapine’s metabolic side effects, notably weight gain and metabolic syndrome. Fixed-dose combinations aim to improve adherence and reduce adverse effects associated with monotherapy.

What is the current market size and projected growth for the drug?

The global antipsychotic drugs market was valued at approximately USD 13.3 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 4-5% through 2028, driven by increasing prevalence of schizophrenia and bipolar disorder, and a growing elderly population. Specific data on Olanzapine; Samidorphan L-malate remains limited due to its late-stage development status and pending regulatory approvals.

How competitive is this therapeutic area?

The market contains established drugs like olanzapine (Zyprexa), risperidone, quetiapine, and aripiprazole. Olanzapine's global sales exceeded USD 3 billion in 2020. The introduction of samidorphan aims to address unmet needs related to metabolic side effects. Similar efforts include the development of other combination therapies and formulations targeting side effect mitigation.

What is the regulatory and developmental status?

As of 2023, Olanzapine; Samidorphan L-malate has advanced through early clinical trials, with Phase III trials initiated in 2020 and ongoing. It was granted Fast Track designation by the FDA in 2021. Regulatory submission for approval is anticipated by 2024, contingent on clinical trial outcomes. The approval timeline influences market entry and revenue expectations.

What are the key financial drivers and potential revenue streams?

Revenue prospects depend on several factors:

• Market penetration: Adoption based on perceived benefits over existing treatments.
• Pricing strategy: Expected premium pricing relative to generic olanzapine, leveraging its side effect mitigation advantage.
• Patient population: Estimated at around 20 million globally with schizophrenia or bipolar disorder, with a subset suitable for this combination.
• Reimbursement and market access: Payer acceptance influences sales volume.

Analysts suggest peak sales potential of USD 1-2 billion annually in markets like the U.S., Europe, and Japan. Adoption rates will depend partially on clinical trial success, safety data, and label indications.

What are the primary challenges influencing growth prospects?

• Regulatory hurdles may delay market entry.
• Competition from line extensions and new formulations.
• Revenue dependency on clinical trial outcomes.
• Payer restrictions driven by cost-effectiveness analyses.
• Market penetration limited by existing generic olanzapine availability.

How do patent expiry and biosimilar/equivalent entries affect the market?

Olanzapine’s primary patents expired around 2011 in the U.S., leading to generic proliferation and price erosion. The new formulation’s exclusivity depends on the patent strength of the combination patent and regulatory data protection. Patent terms may extend into the late 2020s or early 2030s. Biosimilar competition is unlikely due to olanzapine being a small molecule, but generic competition on plain olanzapine remains robust.

What are the strategic opportunities and risks?

Opportunities:

• First-mover advantage in side effect management combination therapy.
• Expansion into other indications such as treatment-resistant depression.
• Partnerships with large pharma to leverage commercial infrastructure.

Risks:

• Clinical or regulatory setbacks.
• Lack of market acceptance if efficacy or safety is not demonstrated.
• Pricing pressures due to generic competition.

---

Key Takeaways

• Olanzapine; Samidorphan L-malate aims to improve schizophrenia and bipolar disorder treatment adherence by reducing metabolic side effects.
• Market growth is driven by increasing disorder prevalence, but late-stage development status tempers near-term revenue forecasts.
• Competition from existing antipsychotics and generics limits potential market penetration.
• Regulatory timing and market access significantly influence revenue expectations.
• Strategic positioning hinges on clinical success, patent protection, and payer acceptance.

Frequently Asked Questions

1. When is Olanzapine; Samidorphan L-malate expected to launch?
Regulatory submission is anticipated by 2024, with approval likelihood contingent on ongoing clinical trial results.

2. How does the drug's pricing compare to existing treatments?
As a novel combination with side effect mitigation, initial pricing may be 20-30% higher than generic olanzapine, targeting premium segments.

3. What are the main competitors in this therapeutic space?
Existing antipsychotics like risperidone, quetiapine, aripiprazole, and their combination therapies.

4. What is the potential impact of patent expiry on revenues?
Patent protection may extend into the late 2020s, delaying generic competition but eventual patent expiration will reduce pricing power.

5. How will reimbursement policies affect market success?
Coverage decisions will depend on demonstrated clinical benefits and cost-effectiveness, influencing formulary placement and patient access.

---

Citations

[1] MarketWatch. "Antipsychotic Drugs Market Size, Share & Trends Analysis Report." 2022.
[2] EvaluatePharma. "Worldwide Sales Data for Olanzapine." 2021.
[3] FDA Official Website. "Fast Track Designation for Olanzapine; Samidorphan Combination." 2021.
[4] IQVIA. "Global Psychotropic Drug Market Analysis." 2022.